BriaCell Therapeutics Corp.
BCT.TO
TSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.51% | -2.92% | -4.82% | -7.64% | -50.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.31% | -31.43% | -27.06% | -39.40% | -25.15% |
| Operating Income | -48.31% | 31.43% | 27.06% | 39.40% | 25.15% |
| Income Before Tax | -553.76% | -467.86% | 44.08% | -197.83% | 48.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -553.76% | -467.86% | 44.08% | -197.83% | 48.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 110.12% | 317.02% | 18.07% | -36.53% | -- |
| Net Income | -566.40% | -457.09% | 44.30% | -196.68% | 49.80% |
| EBIT | -48.31% | 31.43% | 27.06% | 39.40% | 25.15% |
| EBITDA | -49.73% | 31.70% | 27.30% | 39.69% | 26.05% |
| EPS Basic | 9.46% | -201.85% | 78.02% | -158.00% | 55.28% |
| Normalized Basic EPS | 7.74% | -200.05% | 78.07% | -157.59% | 56.04% |
| EPS Diluted | 9.34% | -201.87% | 78.02% | 55.70% | 55.97% |
| Normalized Diluted EPS | 7.74% | -200.05% | 78.07% | -160.09% | 56.04% |
| Average Basic Shares Outstanding | 635.82% | 250.80% | 153.52% | 66.76% | 12.24% |
| Average Diluted Shares Outstanding | 635.82% | 250.80% | 153.52% | 59.71% | 12.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |